Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis | Synapse
March 3, 2026Open Access
Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis
Key Points
Biochemical incomplete response indicates potential progression in patients with thyroid cancer.
Key metrics are sTg levels higher than 50.0 ng/mL and T3b-T4 stages, pointing towards disease progression.
Clinical markers were identified through a retrospective analysis of patient outcomes from initial treatments.
These findings highlight the need for intensified monitoring and possible re-evaluation of therapeutic strategies.
Abstract
sTg≥50.0 ng/mL and T3b-T4 stage are robust, clinically accessible markers identifying PD among BIR patients, warranting intensified surveillance and potentially earlier therapeutic reconsideration.